Organon to be Acquired by Sun Pharma for $14.00/Share in All-Cash Deal, Valuing Company at $11.75B
OGN has more than doubled off its 52-week low of $5.69 on elevated volume (5.5× avg).
Summary
Organon & Co. has entered into a definitive merger agreement to be acquired by Sun Pharmaceutical Holdings USA, Inc. for $14.00 per share in an all-cash transaction, representing an enterprise value of $11.75 billion.
Key Events · M&A and Partnerships · OGN
-
Definitive Merger Agreement Signed
Organon & Co. has entered into a definitive Agreement and Plan of Merger to be acquired by Sun Pharmaceutical Holdings USA, Inc.
-
All-Cash Acquisition at $14.00 Per Share
Each outstanding share of Organon common stock will be converted into the right to receive $14.00 in cash, representing a premium over the current trading price and the unaffected share price.
-
$11.75 Billion Enterprise Valuation
The transaction values Organon at an enterprise value of $11.75 billion, significantly exceeding its current market capitalization.
-
Leadership Roles Confirmed
Joseph Morrissey has been permanently appointed Chief Executive Officer and Carrie S. Cox as Executive Chair, confirming their interim roles.
Analysis · OGN · Life Sciences
This 8-K officially announces the definitive merger agreement for Organon & Co. to be acquired by Sun Pharmaceutical Holdings USA, Inc. for $14.00 per share in cash. This all-cash transaction, with an enterprise value of $11.75 billion, represents a significant premium over the company's unaffected share price and a notable premium over the current trading price of $13.0495. The acquisition will result in Organon becoming a wholly-owned subsidiary of Sun Pharma, providing a clear exit for current shareholders. The deal is subject to regulatory approvals and Organon stockholder approval, with an expected close in early 2027. This is a transformational event for Organon, fundamentally altering its future as an independent public entity. The stock is currently trading near its 52-week high, and the acquisition price offers a further upside for shareholders.
At the time of this filing, OGN was trading at $13.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $5.69 to $13.25. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.